BioXcel Therapeutics (BTAI) Competitors $1.96 +0.09 (+4.81%) Closing price 04:00 PM EasternExtended Trading$1.88 -0.08 (-3.83%) As of 05:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock BTAI vs. ELYM, ATNM, HOWL, LVTX, OKUR, CELU, ATRA, SCYX, ITRM, and ALVRShould you be buying BioXcel Therapeutics stock or one of its competitors? The main competitors of BioXcel Therapeutics include Eliem Therapeutics (ELYM), Actinium Pharmaceuticals (ATNM), Werewolf Therapeutics (HOWL), LAVA Therapeutics (LVTX), OnKure Therapeutics (OKUR), Celularity (CELU), Atara Biotherapeutics (ATRA), SCYNEXIS (SCYX), Iterum Therapeutics (ITRM), and AlloVir (ALVR). These companies are all part of the "pharmaceutical products" industry. BioXcel Therapeutics vs. Eliem Therapeutics Actinium Pharmaceuticals Werewolf Therapeutics LAVA Therapeutics OnKure Therapeutics Celularity Atara Biotherapeutics SCYNEXIS Iterum Therapeutics AlloVir BioXcel Therapeutics (NASDAQ:BTAI) and Eliem Therapeutics (NASDAQ:ELYM) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, valuation, community ranking, risk, media sentiment and profitability. Which has preferable valuation and earnings, BTAI or ELYM? Eliem Therapeutics has lower revenue, but higher earnings than BioXcel Therapeutics. Eliem Therapeutics is trading at a lower price-to-earnings ratio than BioXcel Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBioXcel Therapeutics$2.27M4.75-$179.05M-$25.97-0.08Eliem TherapeuticsN/AN/A-$35.12M-$0.53-2.40 Which has more volatility and risk, BTAI or ELYM? BioXcel Therapeutics has a beta of 0.64, suggesting that its stock price is 36% less volatile than the S&P 500. Comparatively, Eliem Therapeutics has a beta of -0.39, suggesting that its stock price is 139% less volatile than the S&P 500. Does the MarketBeat Community believe in BTAI or ELYM? BioXcel Therapeutics received 238 more outperform votes than Eliem Therapeutics when rated by MarketBeat users. Likewise, 67.67% of users gave BioXcel Therapeutics an outperform vote while only 56.25% of users gave Eliem Therapeutics an outperform vote. CompanyUnderperformOutperformBioXcel TherapeuticsOutperform Votes24767.67% Underperform Votes11832.33% Eliem TherapeuticsOutperform Votes956.25% Underperform Votes743.75% Do analysts rate BTAI or ELYM? BioXcel Therapeutics currently has a consensus target price of $42.60, indicating a potential upside of 2,073.47%. Given BioXcel Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe BioXcel Therapeutics is more favorable than Eliem Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioXcel Therapeutics 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.67Eliem Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media prefer BTAI or ELYM? In the previous week, BioXcel Therapeutics had 2 more articles in the media than Eliem Therapeutics. MarketBeat recorded 2 mentions for BioXcel Therapeutics and 0 mentions for Eliem Therapeutics. BioXcel Therapeutics' average media sentiment score of 1.43 beat Eliem Therapeutics' score of 0.00 indicating that BioXcel Therapeutics is being referred to more favorably in the media. Company Overall Sentiment BioXcel Therapeutics Positive Eliem Therapeutics Neutral Do insiders & institutionals have more ownership in BTAI or ELYM? 30.7% of BioXcel Therapeutics shares are held by institutional investors. Comparatively, 69.8% of Eliem Therapeutics shares are held by institutional investors. 21.2% of BioXcel Therapeutics shares are held by insiders. Comparatively, 4.7% of Eliem Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Is BTAI or ELYM more profitable? Eliem Therapeutics has a net margin of 0.00% compared to BioXcel Therapeutics' net margin of -3,119.33%. BioXcel Therapeutics' return on equity of 0.00% beat Eliem Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets BioXcel Therapeutics-3,119.33% N/A -105.04% Eliem Therapeutics N/A -47.03%-45.97% SummaryBioXcel Therapeutics beats Eliem Therapeutics on 13 of the 18 factors compared between the two stocks. Get BioXcel Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BTAI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BTAI vs. The Competition Export to ExcelMetricBioXcel TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$10.75M$6.73B$5.49B$7.82BDividend YieldN/A3.11%5.42%4.24%P/E Ratio-0.067.2922.4018.49Price / Sales4.75241.63394.60104.26Price / CashN/A65.8538.1834.62Price / Book-0.066.366.724.21Net Income-$179.05M$143.17M$3.22B$248.18M7 Day Performance14.62%8.07%6.61%7.24%1 Month Performance-7.55%-1.39%-0.88%0.52%1 Year Performance-95.34%-1.55%17.17%4.93% BioXcel Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BTAIBioXcel Therapeutics4.424 of 5 stars$1.96+4.8%$42.60+2,073.5%-95.6%$10.75M$2.27M-0.0690Short Interest ↓Positive NewsELYMEliem TherapeuticsN/A$1.26flatN/A-68.1%$37.49MN/A-2.389ATNMActinium Pharmaceuticals1.75 of 5 stars$1.20-0.8%$7.40+516.7%N/A$37.44M$81,000.00-0.8630Analyst ForecastGap DownHOWLWerewolf Therapeutics2.1372 of 5 stars$0.83-9.7%$9.00+984.6%-86.8%$37.20M$1.89M-0.5440Upcoming EarningsLVTXLAVA Therapeutics2.3522 of 5 stars$1.40+6.6%$3.17+126.7%-52.0%$36.75M$11.98M-1.3660Short Interest ↓OKUROnKure Therapeutics3.4352 of 5 stars$2.73-5.5%$32.33+1,084.4%N/A$36.68MN/A-0.22N/APositive NewsCELUCelularity0.3373 of 5 stars$1.52-2.3%N/A-46.7%$36.19M$48.20M0.00220Gap UpATRAAtara Biotherapeutics4.0223 of 5 stars$6.14-0.5%$17.75+189.1%-57.6%$35.97M$128.94M-0.24330Positive NewsSCYXSCYNEXIS1.0395 of 5 stars$0.92+1.7%N/A-33.8%$35.86M$3.75M-1.2460ITRMIterum Therapeutics2.5762 of 5 stars$1.03-4.6%$5.00+385.4%-24.6%$35.62MN/A-0.7910Short Interest ↓ALVRAlloVirN/A$6.99+4.3%N/A-63.5%$35.25MN/A-0.35110 Related Companies and Tools Related Companies Eliem Therapeutics Alternatives Actinium Pharmaceuticals Alternatives Werewolf Therapeutics Alternatives LAVA Therapeutics Alternatives OnKure Therapeutics Alternatives Celularity Alternatives Atara Biotherapeutics Alternatives SCYNEXIS Alternatives Iterum Therapeutics Alternatives AlloVir Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BTAI) was last updated on 4/28/2025 by MarketBeat.com Staff From Our PartnersWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | Sponsored‘Wheels Are Falling Off’ the U.S. Stock MarketThe last time the U.S. economy looked like this, stocks didn't move for 16 years... And many investors lost...Stansberry Research | SponsoredThe Last Time This Happened, Americans Lost BillionsWall Street leaders just held a secret meeting in Las Vegas. What they discussed mirrors 2006 — and the warnin...Banyan Hill Publishing | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | Sponsored"I'm risking my reputation on this"I've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredHere’s How to Claim Your Stake in Elon’s Private Company, xAIEven though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioXcel Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioXcel Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy BTAI Stock Free BTAI Stock Alerts